A comprehensive review on antibody-drug conjugates (ADCs) in the treatment landscape of non-small cell lung cancer (NSCLC)
Chemotherapy, the most commonly used anticancer treatment, has proven benefits over many decades. However, benefits are limited by a relatively narrow therapeutic index and non-selective mechanism of action leading to systemic toxicity. The evolution of targeted therapy in cancers treatment has resulted in a significant survival improvement. Immunotherapy-based strategies including monoclonal antibodies significantly improved mortality in patients with non-small cell lung cancer (NSCLC) [1]. However, the majority of patients will develop acquired resistance to either targeted therapy or immunotherapy, necessitating alternate treatment.
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Abuhelwa Ziad, Alloghbi Abdurahman, Nagasaka Misako Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Immunotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Toxicology